Y Intercept Hong Kong Ltd Invests $731,000 in Dianthus Therapeutics, Inc. $DNTH

Y Intercept Hong Kong Ltd acquired a new position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) in the third quarter, Holdings Channel reports. The institutional investor acquired 18,568 shares of the company’s stock, valued at approximately $731,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after purchasing an additional 618 shares during the period. AlphaQuest LLC bought a new position in shares of Dianthus Therapeutics during the 2nd quarter worth about $94,000. Ensign Peak Advisors Inc bought a new position in Dianthus Therapeutics in the second quarter worth approximately $2,504,000. American Century Companies Inc. lifted its holdings in shares of Dianthus Therapeutics by 13.2% in the 2nd quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock worth $1,009,000 after purchasing an additional 6,323 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in shares of Dianthus Therapeutics in the second quarter valued at $503,000. Institutional investors and hedge funds own 47.53% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on DNTH. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group raised their price objective on shares of Dianthus Therapeutics from $66.00 to $81.00 and gave the stock a “buy” rating in a report on Monday. Truist Financial boosted their target price on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush reissued an “outperform” rating and issued a $46.00 price target on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Finally, HC Wainwright boosted their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $66.50.

Insider Activity

In related news, CFO Ryan Savitz sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Simrat Randhawa sold 109,031 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $38.14, for a total value of $4,158,442.34. Following the completion of the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $152,560. The trade was a 96.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 216,538 shares of company stock valued at $8,283,175 over the last 90 days. 16.56% of the stock is currently owned by company insiders.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $53.18 on Tuesday. Dianthus Therapeutics, Inc. has a 52-week low of $13.36 and a 52-week high of $57.50. The company has a fifty day moving average of $43.98 and a 200-day moving average of $35.47. The stock has a market capitalization of $2.30 billion, a price-to-earnings ratio of -15.28 and a beta of 1.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.11). Dianthus Therapeutics had a negative return on equity of 33.02% and a negative net margin of 4,106.04%.The business had revenue of $0.40 million during the quarter, compared to the consensus estimate of $0.58 million. On average, equities research analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.